Fortis Healthcare Limited — Investor Meet, 13-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Fortis Healthcare reported consolidated revenues of INR 1,988 crores for Q2 FY '25, marking a 12.3% year-on-year growth. The hospital segment saw revenues increase by 13.9% to INR 1,655 crores, while diagnostics revenue reached INR 372 crores, slightly up from INR 360 crores. Consolidated operating EBITDA rose 31.9% to INR 435 crores, improving the margin to 21.9% from 18.6% in Q2 FY '24. The profit after tax before exceptional items surged 40.3% to INR 253 crores. For H1 FY '25, revenues totaled INR 3,847.3 crores, reflecting consistent growth across segments.

2. Future Outlook and Growth Drivers: Management emphasized a focus on expanding hospital capacity and enhancing specialty medical services. Strategic initiatives include investment in new technologies and an ongoing emphasis on digitalization to drive patient engagement and operational efficiencies.

3. Order Book and Operational Updates: The operational occupancy in hospitals improved to 72%, with significant contributions from key specialty areas like oncology and neurosciences. The launch of new facilities, including a brownfield expansion in Manesar with 350 beds, is expected to boost patient capacity and service offerings.

4. Analyst Q&A Insights (Detailed):

- Revenue and Profitability: Analysts probed into the consistent margin improvement, with management citing higher occupancy and effective cost management. Certain hospitals, notably Mulund and Nagarabhavi, showed substantial growth.

- Market Position and Competitive Landscape: There were discussions around the resilience of Fortis’s market position, with assurance of strategic adaptations to maintain competitive advantage amid evolving market dynamics.

- Operational Challenges or Risks: Analysts inquired about potential supply chain and cost pressures, to which management responded confidently, addressing specific strategies to mitigate risks.

- Capex and Capital Allocation: Conversations touched on capital outlays related to the acquisition of stake in Agilus and its impact on balance sheet health; management reaffirmed that the company will pursue additional growth opportunities aligned with overall strategy.

- Strategic Priorities and Long-Term Vision: Analysts asked about long-term goals, with management affirming a commitment to enhancing operational efficiencies and pursuing innovative care solutions.

5. Market or Regulatory Updates: During the call, it was noted that approval for the acquisition of the additional stake in Agilus had been granted, which should enhance control and integration within the diagnostics segment.

6. Strategic Focus Areas: The emphasis on digitalization, expansion of medical services, and the consolidation of Agilus' stake were apparent. Management's positive tone suggested strong confidence in sustained growth and operational efficiency.

7. Investor Insight: Fortis Healthcare’s robust financials and strategic initiatives present a favorable outlook for potential growth. Given the revenue trajectory and operational enhancements, the current positioning leans towards a 'buy' stance, particularly as the company navigates its expansion plans and digital enhancements in diagnostics and hospital services.